BICO News Feed

Discover the latest news from our business areas.

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology

Share on facebook
Share on twitter
Share on linkedin

Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. BICO has a robust portfolio of bioprinters, utilizing extrusion based, 2PP and DLP technologies.  

 BICO has acquired all the shares in San Diego-based Allegro 3D Inc. (“Allegro 3D”) for an up-front enterprise value of USD 6 million. Additionally, the shareholders can receive USD 5 million in an earnout payment contingent on Allegro 3D’s financial performance in the coming two years. The entire purchase price will be paid in cash. Allegro 3D’s patented light-based printing technology will be commercialized by CELLINK and is a strong complement to the existing offering of application-tailored products, as the technology will allow customers greater ability to increase precision and scale their output of bio-fabricated constructs for regenerative medicine and drug discovery purposes. 

 “The acquisition of Allegro 3D is in-line with our M&A strategy of add-on acquisitions where Allegro 3D complements CELLINK’s product portfolio strongly and can quickly be integrated into the current product offering and commercialization infrastructure.” comments BICO Head of M&A Jacob Thordenberg  


 Acquisition rationale  

The addition of Allegro 3D’s bioprinting portfolio brings a tremendous injection in opportunities to scale operations for bioprinting customers. Given the high throughput nature of the technique, customers will be able to increase their output of bio-fabricated constructs. The Allegro 3D portfolio enables high precision and high speed bioprinting that is tailored for multi-well printing, providing life science companies the features needed for developing tissue constructs for regenerative medicine and drug testing workflows. 

 The acquisition is in line with BICO’s commercial agenda to provide technologies and sustainable solutions that bring us closer to a world where on-demand tissue is a reality, reducing the dependency on animal models. With Allegro 3D, BICO continues to add complementary bioprinting methods to the group. Adding to the CELLINK portfolio enables the company to strengthen its position as the global leader in providing bioprinters. With a robust portfolio of extrusion, 2PP and DLP printers, Allegro 3D’s patented printing technology is a strong complement to CELLINK’s existing offer of application-tailored products. 

 The company will remain an independent entity but will be integrated into the commercial structure of global bioprinting leader, CELLINK, another company in the BICO bioprinting business area. 

More news

May 16, 2022 | Bico

BICO joins The North American 3Rs Collaborative’s (NA3RsC) Microphysiological Systems (MPS) Initiative

May 12, 2022 | Bico

BICO Group Adds Senior IR Manager to Its Executive Management

May 11, 2022 | Dispendix

SLAS Europe 2022 – Dublin

May 6, 2022 | Cellenion

cellenONE Training & Workshop – June 2022

May 6, 2022 | Cellink

BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology

May 5, 2022 | Cellink

CELLINK Announces CTR Scientific as Exclusive Distributor in Mexico

May 3, 2022 | Cytena

CYTENA and ExcellGene to Develop Automated Workflows for Biotherapeutics Cell Line Development

May 2, 2022 | Dispendix

OKR’s & Fun

April 22, 2022 | Dispendix

Happy Earth Day

April 21, 2022 | Cellink

CELLINK Enters a Collaboration Agreement with Zoan BioMed to Develop Bioinks for Bone Regeneration and Coral Restoration

April 14, 2022 | Cytena

CYTENA has received the Jobmotor 2021 award for job growth

April 13, 2022 | Scienion

SCIENION GmbH feiert Grundsteinlegung für neue Unternehmenszentrale in Berlin Adlershof

April 13, 2022 | Scienion

SCIENION celebrates the laying of the foundation stone for new headquarters in Berlin Adlershof

April 4, 2022 | Cytena


March 3, 2022 | Cellenion

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence

March 2, 2022 | Scienion

SCIENION Announces Study Results for PoC-BoSens, an Optofluidic-based Infectious Disease Diagnostic Platform

November 16, 2021 | Cellenion

Cellenion Announces Co-Marketing Agreement with Bruker to Deliver Advanced Solutions for Single Cell Mass Spectrometry-Based Proteomics Analysis